Transperineal prostate biopsy: similar cancer detection rate, fewer complications

  • Lo KL & al.
  • Hong Kong Med J
  • 1 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Transperineal ultrasound-guided (TPUS) prostate biopsy is safer than transrectal ultrasound-guided (TRUS) prostate biopsy, with no infection complications and a similar prostate cancer detection rate.

Why this matters

  • The rate of post-TRUS biopsy sepsis is rising worldwide.

Study design

  • Researchers studied the health records of patients who underwent either TPUS prostate biopsy (n=100; mean age, 67.7±6.2 years) or TRUS prostate biopsy (n=100; mean age, 69.1±8.2 years), comparing prebiopsy patient parameters, pathological results, and 30-day complication and readmission rates between groups.
  • Funding: None.

Key results

  • Researchers found similar cancer detection rates for the TPUS group (35%) and TRUS group (25%; both P=.123), even after stratification by PSA density and clinical staging.
  • No patients in either group showed clinical signs of sepsis, but 4% in the TRUS group developed fever requiring hospital readmission for intravenous antibiotic treatment (P=.121).

Limitations

  • The study was retrospective and single center, with a small sample size.
  • All patients had 10 cores taken regardless of biopsy technique or prostate size, which may have reduced cancer detection rates in those with larger prostates.